Prostanoid compounds and pharmaceutical compositions
AssigneeGlaxo Group Limited
InventorsEric W. Collington, Harry Finch, Roger F. Newton, Christopher J. Wallis
Life of this patent
Estimating the term…
Abstract
Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.
Claims7
Prostanoids of the general formula (1) ##STR288## X is cis or trans --CH.dbd.CH--or (CH.sub.2).sub.2 --;
- R.sup.1 is straight or branched C.sub.1-7 alkyl bearing as a terminal substituent --COOR.sup.10 where R.sup.10 is a hydrogen atom, C.sub.1-6 alkyl or C.sub.7-10 phenalkyl;
- Y represents (i) --NR.sup.2 R.sup.3 where R.sup.2 and R.sup.3 are the same or different and are each a hydrogen atom, phenalkyl having C.sub.1-7 alkyl portion or C.sub.1-10 alkyl, both alkyls being optionally substituted by one or more substituents --OR.sup.7 (where R.sup.7 is a hydrogen atom, C.sub.1-7 alkyl, phenyl or phenyalkyl having a C.sub.1-4 alkyl portion) or --NR.sup.8 R.sup.9 (where R.sup.8 and R.sup.9 are the same or different and are each a hydrogen atom or C.sub.1-4 alkyl, or where --NR.sup.8 R.sup.9 is a saturated heterocyclic amino group as defined below for Y);
- any phenyl group in R.sup.2 or R.sup.3 being optionally substituted by one or more C.sub.1-4 alkyl or trifluoromethyl groups;
- always provided that the total numbers of carbon atoms in the group --NR.sup.2 R.sup.3 does not exceed 15;
- or (ii) a saturated heterocyclic amino group selected from the group consisting of pyrrolidino, piperdino, morpholino, piperazino, thiamorpholino, 1-dioxothiamorpholino, homomorpholino, hexamethyleneimino, piperazino substituted at the second nitrogen atom by C.sub.1-7 alkyl or phenalkyl having a C.sub.1-4 alkyl portion, and piperidino which contains in the ring the group C(OH)R.sup.6 (where R.sup.6 is a hydrogen atom, C.sub.1-7 alkyl, phenyl, or phenalkyl having a C.sub.1-4 alkyl portion) and any of said groups substituted on the ring by one or more C.sub.1-4 alkyl groups;
- R.sup.4 is a hydrogen atom, C.sub.1-6 alkyl (optionally interrupted by one or two oxygen atoms), C.sub.3-6 alkenyl, C.sub.2-4 alkanoyl, phenalkanoyl having a C.sub.2-4 alkanoyl portion, phenyl or aralkyl selected from the group consisting of benzyhydryl, naphthyl (C.sub.1-3) alkyl and phen(C.sub.1-3) alkyl and any one of said aryl groups substituted by one or more halogen, hydroxy, C.sub.1-6 alkyl C.sub.1-6 alkoxy, C.sub.1-4 hydroxyalkoxy, trifluoromethyl, cyano, phenyl, phenoxy, C.sub.5-7 cycloalkyl, phenalkoxy dimethylaminomethyl, carboxamido (--CONH.sub.2), thiocarboxamido (--CSNH.sub.2), C.sub.1-4 alkanoyl or --NR.sup.8 R.sup.9 groups as defined above);
- R.sup.5 is as defined above for R.sup.4, excluding phenyl;
- and the physiologically acceptable salts thereof;
- provided that when both R.sup.4 and R.sup.5 are hydrogen atoms and Y is the group --NR.sup.2 R.sup.3 in which R.sup.2 is a hydrogen atom or C.sub.1-4 alkyl, R.sup.3 is not an alkyl group which is only substituted by a hydroxy group.
Dependencies are inferred from the claim text.